GSK1795091 + pembrolizumab

GSK1795091 + pembrolizumab is an investigational combination therapy comprising a synthetic TLR4 agonist (GSK1795091) and an anti–PD-1 monoclonal antibody (pembrolizumab) developed for use in advanced solid tumors. **GSK1795091** is designed to activate the innate immune response by stimulating Toll-like receptor 4, leading to increased cytokine and chemokine production, antigen presentation, and T cell activation. **Pembrolizumab** blocks the programmed cell death protein 1 (PD-1) pathway, releasing the inhibition on cytotoxic T lymphocytes and enhancing anti-tumor immune responses. The combination aims to synergistically enhance cancer immunotherapy effectiveness. GSK1795091 has been through phase I trials with pembrolizumab in patients with advanced cancers, showing immune activation and a toxicity profile typical for immunostimulatory agents, though with limited anti-tumor efficacy data[1][3][4].